Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2015

01-08-2015 | Thoracic Oncology

Clinical Significance of SIP1 and E-cadherin in Patients with Esophageal Squamous Cell Carcinoma

Authors: Rintaro Yoshida, MD, PhD, Masaru Morita, MD, PhD, Fumihiro Shoji, MD, PhD, Yuichiro Nakashima, MD, PhD, Naoko Miura, MD, PhD, Keiji Yoshinaga, MD, PhD, Tadashi Koga, MD, PhD, Eriko Tokunaga, MD, PhD, Hiroshi Saeki, MD, PhD, Eiji Oki, MD, PhD, Yoshinao Oda, MD, PhD, Yoshihiko Maehara, MD, PhD

Published in: Annals of Surgical Oncology | Issue 8/2015

Login to get access

Abstract

Background

Epithelial-mesenchymal transition (EMT), when epithelial cells convert to mesenchymal cells, influences cancer invasion and metastasis. Smad interacting protein 1 (SIP1) is an EMT trigger, which is inversely correlated with E-cadherin in some carcinomas. To elucidate the role of SIP1 in esophageal squamous cell carcinoma (ESCC), the status of EMT and the clinicopathological features were evaluated.

Methods

Immunohistochemical (IHC) analyses of 111 human ESCC tissue specimens for SIP1 and E-cadherin were performed, and the relationships between the expression and clinicopathological features were evaluated.

Results

IHC analyses of esophageal tumors showed the expression of SIP1 and E-cadherin to be significantly inversely correlated. Significant correlations between the SIP1 expression and clinicopathological variables such as differentiation, depth of invasion, vascular invasion, and pathological stage were also seen. Conversely, tumors with a weak expression of E-cadherin tended to exhibit greater histological differentiation. Logistic regression analyses revealed a positive SIP1 expression, lymphatic invasion, and vascular invasion to be factors predicting lymph node (LN) metastasis. Univariate survival analyses revealed a positive SIP1 expression predicted a poorer overall survival than a negative expression.

Conclusion

These results suggest that SIP1 is correlated with LN metastasis and may therefore be an independent marker for metastasis in patients with ESCC.
Literature
1.
Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000; 232(2):225-32.PubMedCentralPubMedCrossRef
2.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-54.PubMedCrossRef
3.
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548-58.PubMedCrossRef
4.
Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006;66(17):8319-26.PubMedCrossRef
5.
6.
7.
Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29(6):493-503.PubMedCrossRef
8.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-90.PubMedCrossRef
9.
Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004;48(5-6):365-75.PubMedCrossRef
10.
Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002;21(20):3241-6.PubMedCrossRef
11.
Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002; 61(5):1881-91.CrossRef
12.
Lee KW, Kim JH, Han S, et al. Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann Surg Oncol. 2012;19(1):326-35.PubMedCrossRef
13.
Bindels S, Mestdagt M, Vandewalle C, et al. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene. 2006;25(36):4975-85.PubMedCrossRef
14.
Verschueren K, Remacle JE, Collart C, et al. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5′-CACCT sequences in candidate target genes. J Biol Chem. 1999;274(29):20489-98.PubMedCrossRef
15.
Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7(6):1267-78.PubMedCrossRef
16.
Remacle JE, Kraft H, Lerchner W, et al. New mode of DNA binding of multi-zinc finger transcription factors: deltaEF1 family members bind with two hands to two target sites. Embo J. 1999;18(18):5073-84.PubMedCentralPubMedCrossRef
17.
Vandewalle C, Comijn J, De Craene B, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 2005;33(20):6566-78.PubMedCentralPubMedCrossRef
18.
Sugimachi K, Tanaka S, Kameyama T, et al. Transcriptional repressor snail and progression of human hepatocellular carcinoma. Clin Cancer Res. 2003;9(7):2657-64.PubMed
19.
Natsugoe S, Uchikado Y, Okumura H, et al. Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep. 2007;17(3):517-23.PubMed
20.
Uchikado Y, Natsugoe S, Okumura H, Setoyama T, Matsumoto M, Ishigami S, et al. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11(3):1174-80.PubMed
21.
Maeda G, Chiba T, Okazaki M, et al. Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression. Int J Oncol. 2005;27(6):1535-41.PubMed
22.
Sobin L, Gospodarowicz M, Wittekind C; International Union Against Cancer. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009.
23.
Miura N, Yano T, Shoji F, et al. Clinicopathological significance of Sip1-associated epithelial mesenchymal transition in non-small cell lung cancer progression. Anticancer Res. 2009;29(10):4099-106.PubMed
24.
Kyo S, Sakaguchi J, Ohno S, et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol. 2006;37(4):431-8.PubMedCrossRef
25.
Sakamoto K, Imanishi Y, Tomita T, et al. Overexpression of SIP1 and downregulation of E-cadherin predict delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma after partial glossectomy. Ann Surg Oncol. 2012;19(2):612-9.PubMedCrossRef
26.
Fang Y, Wei J, Cao J, et al. Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One. 2013;8(5):e62558.PubMedCentralPubMedCrossRef
27.
Imamichi Y, Konig A, Gress T, Menke A. Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene. 2007;26(16):2381-5.PubMedCrossRef
28.
Xia M, Hu M, Wang J, Xu Y, Chen X, Ma Y, et al. Identification of the role of Smad interacting protein 1 (SIP1) in glioma. J Neurooncol. 2010;97(2):225-32.PubMedCrossRef
29.
Sayan AE, Griffiths TR, Pal R, et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA. 2009;106(35):14884-9.PubMedCentralPubMedCrossRef
30.
Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, et al. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer. 2004;90(6):1265-73.PubMedCentralPubMedCrossRef
31.
Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23.PubMedCentralPubMedCrossRef
32.
33.
Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98(10):1512-20.PubMedCrossRef
34.
35.
36.
Elloul S, Elstrand MB, Nesland JM, et al. Snail, slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103(8):1631-43.PubMedCrossRef
37.
Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, Soini Y. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat. 2013;138(1):81-90.PubMedCrossRef
38.
Okugawa Y, Inoue Y, Tanaka K, et al. Smad interacting protein 1 (SIP1) is associated with peritoneal carcinomatosis in intestinal type gastric cancer. Clin Exp Metastasis. 2013;30(4):417-29.PubMedCrossRef
Metadata
Title
Clinical Significance of SIP1 and E-cadherin in Patients with Esophageal Squamous Cell Carcinoma
Authors
Rintaro Yoshida, MD, PhD
Masaru Morita, MD, PhD
Fumihiro Shoji, MD, PhD
Yuichiro Nakashima, MD, PhD
Naoko Miura, MD, PhD
Keiji Yoshinaga, MD, PhD
Tadashi Koga, MD, PhD
Eriko Tokunaga, MD, PhD
Hiroshi Saeki, MD, PhD
Eiji Oki, MD, PhD
Yoshinao Oda, MD, PhD
Yoshihiko Maehara, MD, PhD
Publication date
01-08-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4314-1

Other articles of this Issue 8/2015

Annals of Surgical Oncology 8/2015 Go to the issue

Thoracic Oncology

Prognostic Significance of 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Colorectal Cancer

Modern Treatment of Rectal Cancer Closes the Gap Between Common Adenocarcinoma and Mucinous Carcinoma

Endocrine Tumors

Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer

Gastrointestinal Oncology

Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer

Head and Neck Oncology

Intratumor Textural Heterogeneity on Pretreatment 18F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer

Gastrointestinal Oncology

Comparison of Reduced Port Totally Laparoscopic Distal Gastrectomy (Duet TLDG) and Conventional Laparoscopic-Assisted Distal Gastrectomy